Clinical Trials Logo

Lymphoma, Mixed Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Mixed Cell, Diffuse.

Filter by:
  • None
  • Page 1

NCT ID: NCT00532259 Completed - Clinical trials for Primary Mediastinal Large B-Cell Lymphoma

CT-011 MAb in DLBCL Patients Following ASCT

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease. Although many people are cured of their lymphoma with this therapy, the disease comes back in a certain proportion of patients. The purpose of this study is to test the safety and effectiveness of the monoclonal antibody, CT-011, in patients with DLBCL who have received autologous peripheral blood stem cell transplantation. All final eligible patients will receive an IV infusion of CT-011 on Day 1 (30 to 90 days post autologous PBSCT). Treatment will be repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85. Follow-up for safety and clinical outcome will be conducted throughout the study till 18 months post autologous PBSCT. Approximately 70 patients will participate in this study.